Branded Drug Makers Criticize E.U. Deal on Data Protection, Generics

Law360, New York (November 5, 2003, 12:00 AM EST) -- European drugmakers raised concerns about moves in the European Parliament to limit the data protection period for new drugs and water down the definition of generic versions, newswires reported.

The European Parliament is expected to complete its second reading of the new EU pharmaceutical legislation next month. A final approval by European Union ministers is expected in the first half of 2004, ahead of E.U. enlargement.

While industry groups representing branded drugmakers generally have embraced the efforts to centralize drug evaluations, they are dismayed by a...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.